COLUMBUS Trial 5-Year Update: Encorafenib/Binimetinib vs Vemurafenib or Encorafenib in Advanced BRAF V600–Mutant Melanoma
Source: The ASCO Post, August 2022
In a 5-year update of part 1 of the phase III COLUMBUS trial reported in the Journal of Clinical Oncology, Dummer et al found a continued benefit of encorafenib plus binimetinib vs vemurafenib in patients with advanced BRAF V600–mutant melanoma. The trial supported the June 2018 approval of encorafenib plus binimetinib in this setting.
Study Details
In the open-label international trial, 577 patients with locally advanced unresectable or metastatic disease who were previously untreated or had disease progression after first-line immunotherapy were randomly assigned 1:1:1 between December 2013 and April 2015 to receive encorafenib at 450 mg once daily plus binimetinib at 45 mg twice daily (n = 192); vemurafenib at 960 mg twice daily (n = 191), or encorafenib at 300 mg once daily (n = 194). The primary endpoint was progression-free survival.